Roche’s response to the COVID-19 pandemic

Coronavirus close up

COVID-19 pandemic

 

Timely availability and fast access to reliable, high quality tests are essential for healthcare systems.

Thomas Schinecker
Chief Executive Officer of Roche Diagnostics

Our commitment to help put a stop to the COVID-19 pandemic

 

Roche is deeply committed to supporting the global response to put an end to the COVID-19 pandemic. Around the world, we are working with urgency, passion and purpose each and every day to deliver high quality tests that are essential for healthcare systems and patients alike.

Detecting SARS-CoV-2 in currently infected patients with high sensitivity

Instrument Icon

Laboratory tests

High-throughput PCR testing on cobas® 6800/8800 Systems

 

 

cobas® SARS-CoV-2 Test

Real-time RT-PCR test intended for the qualitative detection of SARS-CoV-2 in nasal, nasopharyngeal and oropharyngeal swab samples from asymptomatic and symptomatic individuals.

 

cobas® SARS-CoV-2 & Influenza A/B Test

Simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A virus, and/or influenza B virus in nasal or nasopharyngeal swab samples collected from individuals suspected of a respiratory viral infection consistent with COVID-19 by their healthcare provider. 

High-throughput testing on cobas® immunochemistry analyzers

 

Elecsys® SARS-CoV-2 Antigen

The Elecsys® SARS-CoV-2 Antigen is an immunoassay for the qualitative detection of the SARS-CoV-2 nucleocapsid antigens.

PoC tests icon

Point of Care tests

Point-of-care PCR testing in just 20 minutes on cobas® Liat® System

 

cobas® SARS-CoV-2 Assay

Authorized for use in screening and testing asymptomatic and symptomatic individuals, cobas® SARS-CoV-2 is a real-time RT-PCR assay intended for the rapid in vitro qualitative detection of SARS-CoV-2.

 

cobas® SARS-CoV-2 & Influenza A/B Assay

For patients presenting with symptoms of respiratory illness or is suspected of a respiratory infection consistent with COVID-19, the cobas® SARS-CoV-2 & Influenza A/B Assay for use with the cobas® Liat® System brings the simultaneous rapid in vitro qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B in an automated multiplex real-time RT-PCR assay for use at the point of care.

 

Rapid Antigen Tests

 

SARS-CoV-2 Rapid Antigen Test

The SARS-CoV-2 Rapid Antigen Test is a reliable, rapid chromatographic immunoassay for the qualitative detection of specific antigens of SARS-CoV-2 present in the human nasopharynx.

 

SARS-CoV-2 Rapid Antigen Test Nasal

The SARS-CoV-2 Rapid Antigen Test Nasal is a reliable, rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen present in human nasal samples.

 

SARS-CoV-2 Antigen Self Test Nasal

The SARS-CoV-2 Antigen Self Test Nasal provides reliable results for individuals suspected of having COVID-19. The Self Test can be performed by the general public, providing another option for decentralized testing.

Detecting a patient’s immune response to SARS-CoV-2 with high specificity

Instrument Icon

Laboratory tests

Antibody tests

 

Elecsys® Anti-SARS-CoV-2 is an immunoassay for the in vitro qualitative detection of antibodies (including IgG) to SARS-CoV-2 in human serum and plasma. The test is intended as an aid in the determination of the immune reaction to SARS-CoV-2.

Elecsys® Anti-SARS-CoV-2 S is an immunoassay for the in vitro quantitative determination of antibodies (including IgG) to the SARS-CoV-2 spike (S) protein receptor binding domain (RBD) in human serum and plasma.

The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers.

Elecsys® Anti-SARS-CoV-2

Elecsys® Anti-SARS-CoV-2 S

Rapid detection or rule-out of co-infections and secondary infections helps improve antibiotic stewardship

When to use which
SARS‑CoV‑2 diagnostic test2

 

Reliable diagnostic tests targeting patients that are currently infected by the virus, as well as those that have an immune response against the virus, are valuable. However, it is important to understand which tests are most suitable to use depending on their intended purpose.

*Whether immunity is gained by individuals who have been infected with SARS-CoV-2 is yet to be confirmed due to the novelty of the virus. Data presented here are based on current scientific understanding of the disease (April 2020)

icon of a person
Is my sickness COVID‑19?
icon of a person
How is my body's immune system reacting to the virus?

Our efforts to aid in epidemiological research

 

We continue our intensive research and development efforts to bring additional solutions to market to help study the spread of COVID-19 and emerging SARS-CoV-2 variants.

cobas® SARS-CoV-2 Variant Set 1

Virus illustration

Abbreviations

 

COVID-19: coronavirus disease 2019

RT-PCR: reverse transcription polymerase chain reaction

 
References
 
  1. Makary, M. et. al. (2021) MedPage Today, https://www.medpagetoday.com/blogs/marty-makary/90795
  2. European Commision (2020). Guidelines on COVID-19 in vitro diagnostic tests and their performance (published 15 April 2020). Available from https://ec.europa.eu/info/sites/info/files/testing_kits_communication.pdf [Accessed April 2020]
  3. Hsu, J. (2020) BMJ;369:m1983, https://www.bmj.com/content/369/bmj.m1983